The Breast
Volume 19, Issue 5 , Pages 333-338 , October 2010

A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer

  • M. Venturini

      Affiliations

    • Oncologia Medica, Ospedale Classificato Sacro Cuore Don Calabria, Via Don A. Sempreboni 5, 37024 Negrar, Verona, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 (0)456013472; fax: +39 (0)456013411.
    • ,
  • C. Bighin

      Affiliations

    • Oncologia Medica, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    • ,
  • F. Puglisi

      Affiliations

    • Oncologia Medica, Azienda Ospedaliera Universitaria, Udine, Italy
    • ,
  • N. Olmeo

      Affiliations

    • Oncologia Medica, Ospedale Civile, Sassari, Italy
    • ,
  • E. Aitini

      Affiliations

    • Oncologia Medica, Ospedale Carlo Poma, Mantova, Italy
    • ,
  • G. Colucci

      Affiliations

    • Oncologia Medica, Istituto Oncologico, Bari, Italy
    • ,
  • O. Garrone

      Affiliations

    • Oncologia Medica, Ospedale Santa Croce e Carle, Cuneo, Italy
    • ,
  • A. Paccagnella

      Affiliations

    • Oncologia Medica, Ospedale Civile, Venezia, Italy
    • ,
  • G. Marini

      Affiliations

    • Oncologia Medica, Spedali Civili, Brescia, Italy
    • ,
  • L. Crinò

      Affiliations

    • Oncologia Medica, Azienda Ospedaliera di Perugia, Italy
    • ,
  • M. Mansutti

      Affiliations

    • Oncologia Medica, Azienda Ospedaliera Universitaria, Udine, Italy
    • ,
  • B. Baconnet

      Affiliations

    • Cephalon France (Maisons Alfort CEDEX)
    • ,
  • A. Barbato

      Affiliations

    • Cephalon Italy (Rome)
    • ,
  • L. Del Mastro

      Affiliations

    • Oncologia Medica, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy

Received 5 August 2009 ,Revised 23 December 2009 ,Accepted 22 January 2010.

References 

  1. Honing SF. Treatment of metastatic disease, hormonal therapy and chemotherapy. In:  Harris JR,  Lippman ME,  Morrow M,  Hellman S editor. Breast diseases. Philadelphia, PA: Lippincott; 1996;p. 669–734
  2. Bergh J, Jonsson PE, Glimelius B, Nygren P. A systematic overview of chemotherapy effects in breast cancer. Acta Oncol. 2001;40:253–281
  3. Hamilton A, Hortobagyi G. Chemotherapy: what progress in the last 5 years?. J Clin Oncol. 2005;23:1760–1775
  4. Lord S, Ghersi D, Gattellari M, Wortley S, Wilcken N, Simes J. Antitumour antibiotic-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. 2004;4:CD003367
  5. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. 2003;21:588–592
  6. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792
  7. Gennari A, Salvadori B, Donati S, Bengala C, Orlandini C, Danesi R, et al. Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors. J Clin Oncol. 1999;17:3596–3602
  8. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869–2879
  9. Von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710–717
  10. Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med. 1977;62:200–208
  11. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215–1221
  12. Tan-Chiu E, Yothers G, Romond E, Geyer CE, Ewer M, Keefe D, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23:7811–7819
  13. Ewer MS, Lippman MS. Type II chemotherapy related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005;13:2900–2902
  14. Dando TM, Keating GM. Liposomal doxorubicin: a review of its use in metastatic breast cancer and potential in non-Hodgkin lymphoma. Am J Cancer. 2005;4:193–206
  15. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001;19:1444–1454
  16. Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast cancer. Cancer. 2002;94:25–36
  17. Batist G, Harris L, Azarnia N, Lee LW, Daza-Ramirez P. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis. Anti-Cancer Drugs. 2006;17:587–595
  18. Leonard RC, Williams S, Tulpule A, Levine AM, Oliveros S. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet). Breast. 2009;18(4):218–224
  19. Venturini M, Bighin C, Monfardini S, Cappuzzo F, Olmeo N, Durando A, et al. Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2006;95:45–53
  20. Marty M, Laurence V, Cottu P, Pierga J-Y, Barton J, Huckle H, et al. A phase I dose escalation study of non-pegylated liposomal doxorubicin (M) and docetaxel (D) in patients (pts) with previously untreated advanced breast cancer. Ann Oncol. 2002;13(Suppl. 5):55;[Abstract 196P]
  21. Trigo J, Climent MA, Lluch A, et al. Liposomal doxorubicin Myocet® in combination with Herceptin® and paclitaxel is active and well tolerated in patients with HER2-positive locally advanced or metastatic breast cancer: a phase II study. Breast Cancer Res Treat. 2003;82(Suppl. 1):S83;[Abstract 351]
  22. Cortes J, Di Cosimo S, Climent MA, Cortés-Funes H, Lluch A, Gascón P, et al. Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/I study. Clin Cancer Res. 2009;15(1):307–314
  23. World Health Organization . Handbook for reporting results of cancer treatment. Geneva: WHO; 1979;
  24. Simon R. Optimal two-stage design for phase II clinical trials. Contr Clin Trials. 1989;10:1–10
  25. Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with cross-over. J Clin Oncol. 2000;18:724–733
  26. Chan S, Friedrichs K, Noel D, Pintér T, Van Belle S, Vorobiof D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1999;17:2341–2354
  27. Paik S, Bryant J, Park C, Fisher b, Tan-Chiu E, Hyams D, et al. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998;90:1361–1370
  28. Pritchard KI, O'Malley FA, Audrulis I, Shepherd LE, Tu D, Levine MN, et al. Prognostic and predictive value of HER-2/neu in a randomized trial comparing CMF to CEF in premenopausal women with auxiliary lymph node positive breast cancer (NCIC CTG MA 5). Proc Am Soc Clin Oncol. 2002;21:42a;[Abstract 165]
  29. Untch M, Eidtmann H, du Bois A, Meerpohl HG, Thomssen Ch, Ebert A, et al. Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial. Eur J Cancer. 2004;40:988–997

PII: S0960-9776(10)00035-4

doi: 10.1016/j.breast.2010.01.018

The Breast
Volume 19, Issue 5 , Pages 333-338 , October 2010

Article Tools

* Image Usage & Resolution